telisotuzumab vedotin-tllv
| Brand name | Emrelis |
|---|---|
| Active ingredient | telisotuzumab vedotin-tllv |
| Strength | 20MG |
| Dosage form | For Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | May 2025 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.